Lunit AI Predicts Immunotherapy Outcomes in Colorectal, Kidney, and Lung Cancer at ESMO 2025

Lunit’s SCOPE IO AI pathology platform was presented at ESMO 2025, showing predictive capability for immunotherapy response in colorectal, kidney, and lung cancers123.

In colorectal cancer trials (AtezoTRIBE and AVETRIC), the AI-generated biomarker stratified patients into biomarker-high and biomarker-low groups; biomarker-high patients receiving immunotherapy had significantly improved progression-free and overall survival compared to biomarker-low groups13.

For advanced clear cell renal cell carcinoma, the AI distinguished inflamed tumors with a 60.5% response rate to nivolumab plus ipilimumab, versus 23.2% for non-inflamed tumors3.

The findings demonstrate the potential of AI-derived tumor microenvironment biomarkers to personalize immunotherapy decisions across multiple cancer types13.

Data were presented during the European Society for Medical Oncology (ESMO) congress, October 17–21, 2025, in Berlin12.

Sources:

1. https://www.medicaldevice-network.com/news/esmo-2025-lunit-ai-tool-predicts-immunotherapy-response-across-cancer-types/

2. https://www.lunit.io/en/company/news

3. https://trial.medpath.com/news/fc3097211f516435/lunit-s-ai-platform-demonstrates-predictive-power-for-immunotherapy-response-across-multiple-cancer-types-at-esmo-2025